CB-101 is a prodrug capable of maintaining a steady state of NaB in the blood, thereby avoiding the side effects associated with high doses of NaB. It converts the excess glycine to hippurate which is excreted in the urine.
Orphan drug designation for the treatment of Huntington's disease granted from the FDA on September 10, 2019.
Orphan drug designation for the treatment of nonketotic hyperglycinemia granted from the FDA on October 15, 2019.
CB-201 is a novel intranasal peptide to hinder the TLR2-MyD88 interaction, thereby specifically reducing the induced TLR2 signaling.
CB-301 is a neutralizing monoclonal antibody highly specific to the p40 homodimer (p402) of IL-12 family.
CB-401 is a human p40 recombinant protein of IL-12 family.